AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

01/05 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
17/10/26	EUR 0.5430	-1.45%	133,938
15/10/26	EUR 0.5510	-1.61%	345,166
14/10/26	EUR 0.5600	-3.45%	154,939
13/10/26	EUR 0.5800	+5.65%	419,375
12/10/26	EUR 0.5490	+4.77%	177,933

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - AB Science

Company calendar

Market Closed - Euronext Paris 02:55:00 17/10/26 am AEDT			After hours 04:37:35 am
0.5430 ^EUR	-1.45%		0.5400	-0.55%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Market Cap	44.09M 49.6M 40.86M 37.18M 70.16M 4.71B 71.28M 491M 193M 2.46B 186M 182M 7.83B	P/E 2024	-5.88x	P/E 2025	-51.2x
Enterprise Value	53.35M 60.02M 49.45M 44.99M 84.9M 5.7B 86.26M 594M 233M 2.97B 225M 220M 9.48B	EV / Sales 2024	63.5x	EV / Sales 2025	103x
Free-Float	72.33%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	AB	Real-time
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Börse Stuttgart	A8D	Delayed
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
11/07	AB Science streamlines its portfolio and refocuses on two molecules
11/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

13/10	AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.	GL
10/10	AB Science : Revenues for the first half of 2026 and update on AB Science’s activities	PU
10/10	AB Science today reports its revenues for the first half of 2026 and provides an update on its activities	GL
29/09	AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection	GL
17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL

13/10	AB Science tiendra une web conférence le mercredi 14 octobre 2026 de 18h à 19h30
12/10	Bourse : LVMH en piste ce soir, Stellantis sort une 2CV, NVidia et Amazon s'offrent des garanties
12/10	La Bourse se découvre une passion pour le cocktail taux-croissance
10/10	AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2026 et présente un point sur ses activités
09/10	Bourse : ça bouge chez Saint-Laurent (Kering) et BNP Paribas, SpaceX s'attaque aux opérateurs mobiles

1 day	-1.45%
1 week	+3.63%
Current month	-7.97%
1 month	-23.41%
3 months	-12.14%
6 months	-54.52%
Current year	-64.65%

1 week	0.53	0.6
1 month	0.51	0.73
Current year	0.5	1.61
1 year	0.5	1.61
3 years	0.5	4.46
5 years	0.5	13.76
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/5/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
9/2/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
2/2/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-1.45%	+3.63%	-61.60%	-79.12%	49.39M
ELI LILLY AND COMPANY	+0.69%	+6.58%	+53.39%	+103.82%	1,116B
JOHNSON & JOHNSON	+0.81%	-2.51%	+32.66%	+61.79%	610B
ABBVIE INC.	+0.58%	+3.00%	+25.52%	+93.42%	501B
MERCK & CO., INC.	+1.19%	+0.89%	+75.04%	+41.05%	358B
ROCHE HOLDING AG	-0.13%	+5.98%	+32.91%	+50.39%	366B
NOVARTIS AG	-0.95%	+4.70%	+19.51%	+43.00%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.86%	+13.43%	261B
AMGEN INC.	-0.09%	+4.60%	+46.70%	+51.26%	235B
GILEAD SCIENCES, INC.	-0.69%	+3.41%	+32.64%	+97.37%	195B
Average	-0.26%	+5.44%	+25.59%	+47.64%	392.98B
Weighted average by Cap.	+0.20%	+4.93%	+39.16%	+71.35%

	2024	2025
Net sales	1.07M 1.21M 994K 904K 1.71M 114M 1.73M 11.94M 4.68M 59.73M 4.53M 4.43M 190M	1.17M 1.32M 1.09M 990K 1.87M 125M 1.9M 13.08M 5.13M 65.41M 4.96M 4.85M 209M
Net income	-7.83M -8.81M -7.26M -6.6M -12.46M -836M -12.66M -87.25M -34.21M -436M -33.06M -32.36M -1.39B	-1.56M -1.75M -1.44M -1.31M -2.48M -166M -2.52M -17.35M -6.8M -86.75M -6.57M -6.43M -277M
Net Debt	10.48M 11.79M 9.72M 8.84M 16.68M 1.12B 16.95M 117M 45.8M 584M 44.26M 43.32M 1.86B	9.26M 10.42M 8.58M 7.81M 14.74M 989M 14.97M 103M 40.45M 516M 39.1M 38.27M 1.64B